dAb ImmunoTech Announced Development of SARS-CoV-2 (COVID-19) IgG and IgM Dual Antibody Test

dAb ImmunoTech, Inc., a novel near Atlanta, GA based immuno-diagnostic company focused on the development of rapid testing solutions for infectious and cancer diseases, today announced the development of the Lateral Flow Immunoassay (LFI) SARS-CoV-2 IgG and IgM Dual Antibody Test Kit. The highly accurate qualitative 10 minutes LFI test can detect the SARS-CoV-2 IgG and IgM antibodies in human serum, plasma and whole blood specimens. The rapid test is often referred to as point-of-care tests because rather than sending a blood sample to a laboratory, the test can be conducted and the result read by naked eyes in a doctor’s office or a community setting or even at home, without specialized laboratory equipment and expertise.

About the dAb ImmunoTech, Inc.
dAb ImmunoTech, Inc. , a US corporation headquartered in near Atlanta, Georgia, is a Immunoassay and Immunodiagnostics company that develops, manufactures and markets a new, state-of-the-art diagnostics product and technology. dAb ImmunoTech is a provider of immuno-diagnostic and biomarker solutions designed to enhance patient care and promote health and individual well-being through cutting-edge science and technology.

For more information see: www.dabimmunotech.com